American Society of Clinical Oncology, June 3-7

The Annual Meeting of the American Society of Clinical Oncology

The annual meeting of the American Society of Clinical Oncology was held from June 3 to 7 in Chicago and attracted more than 40,000 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in oncology. The conference featured the latest advances in clinical cancer research, including oral abstract presentations and poster presentations in disease-based and specialty tracks. Presentations focused on novel targeted therapies as well as improvements in chemotherapy and radiation therapy approaches.

In the TROPiCS-02 phase 3 clinical trial, Hope S. Rugo, M.D., of the University of California San Francisco Comprehensive Cancer Center, and colleagues found that the use of sacituzumab govitecan improves median progression-free survival (PFS) compared with standard chemotherapy in patients with heavily pretreated endocrine-resistant hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer.

The authors evaluated the effectiveness of sacituzumab govitecan compared to the physician’s choice of chemotherapy for advanced HR+/HER2− breast cancer. At 113 international locations, 543 patients with HR+/HER2− metastatic breast cancer who had been treated with endocrine therapy, CDK4/6 inhibitors, and two to four chemotherapy regimens were enrolled. The researchers found that sacituzumab govitecan improved median PFS by 34 percent compared with standard chemotherapy; there was also a nonsignificant trend seen in overall survival. The overall response rate was 21 percent for those who received sacituzumab govitecan compared with 14 percent for those who received standard chemotherapy. Furthermore, the investigators found that the clinical benefit rate and median duration of response both favored sacituzumab govitecan.

“In TROPiCS-02, sacituzumab was studied in patients who had very heavily pretreated hormone receptor-positive advanced breast cancer, with very limited options, and offers a potential for another effective therapy for these patients,” Rugo said. “Overall, it is important to have new treatment options, extend quality of life, and provide disease control for patients with heavily pretreated hormone receptor-positive advanced cancer.”

The study was funded by Gilead Sciences, the manufacturer of sacituzumab govitecan.

Press Release

In the single-arm prospective phase 3 LUMINA trial, Timothy Joseph Whelan, M.D., of McMaster University and the Juravinski Cancer Centre in Hamilton, Ontario, Canada, and colleagues found that the rate of recurrence is very low among women 55 years or older with luminal A breast cancer not treated with radiation.

1 | 2 | 3 | 4
Page 1 of 4
Next »